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Abstract
Introduction: Cavernous sinus invasion by pituitary adenoma affects surgical procedure radicality and consequently the postoperative course 
and prognosis in pituitary adenoma treatment. The search for pituitary adenoma aggressive behaviour markers is still a matter of debate. 
Material and methods: This study evaluates the relation of pituitary adenoma invasiveness to the expression of topoisomerase IIα in 72 
patients who underwent transsphenoidal pituitary surgery. The assessment of tumour growth was conducted according to the Hardy scale 
as modified by Wilson and the Knosp scale. Topoisomerase IIα expression in tumour specimens was evaluated using immunohistochemical 
staining. 
Results: There was a correlation between the Knosp scale degree and the topoisomerase IIα expression (Spearman R = 0.3611, p < 0.005). 
The Kruskal-Wallis H test (p = 0.0034) showed that there was a statistically significant topoisomerase IIα expression increase in tumours 
classified as grade E on the Hardy scale. The topoisomerase IIα expression correlated also with tumour size (Spearman R = 0.4117, 
p < 0.001). Higher levels of expression were observed in macroadenomas, as compared to microadenomas (p < 0.05, Mann-Whitney test). 
Topoisomerase IIα expression correlated with cavernous sinus invasion. 
Conclusions: The topoisomerase IIα expression correlated more with invasiveness than with extensiveness, which might make it an 
eminently useful marker in the assessment of aggressive pituitary adenoma behaviour. (Endokrynol Pol 2018; 69 (5): 530–535)
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Streszczenie
Wstęp: Naciekanie zatok jamistych przez gruczolaka przysadki wpływa na radykalność zabiegu operacyjnego, a w konsekwencji na 
przebieg pooperacyjny i rokowanie. Do chwili obecnej nie ustalono jednak, jakie markery najlepiej odzwierciedlają agresywne zacho-
wanie gruczolaków przysadki. 
Materiał i metody: W badaniu oceniono związek między inwazyjnością gruczolaków przysadki a ekspresją topoizomerazy IIα w grupie 
72 pacjentów po przebytej przezklinowej operacji z powodu gruczolaka przysadki. Zaawansowanie guza oceniano stosując skalę Hardy’ego 
w modyfikacji Wilsona i skalę Knospa. Ekspresję topoizomerazy IIα w wycinkach guza oceniano w badaniu immunohistochemicznym. 
Wyniki: Stwierdzono istotną korelację między zaawansowaniem gruczolaka przysadki według skali Knospa a ekspresją topoizomerazy 
IIα (współczynnik korelacji R Spearmana 0,3611, p < 0,005). Stwierdzono istotny wzrost ekspresji topoizomerazy IIα w guzach w stopniu 
zaawansowania E wg skali Hardy’ego (test H Kruskal-Wallisa, p = 0,0034). Ekspresja topoizomerazy IIα korelowała także z wielkością 
guza (współczynnik korelacji R Spearmana 0,4117, p < 0,001). Wyższe wartości indeksu ekspresji obserwowano w makrogruczolakach w 
porównaniu z mikrogruczolakami (p < 0,05, test Manna-Whitneya). Ekspresja topoizomerazy IIα korelowała z naciekaniem zatok jamistych. 
Wnioski: Ekspresja topoizomerazy IIα lepiej koreluje z inwazyjnością gruczolaków przysadki niż z ekstensywnością ich wzrostu. Może 
więc być bardzo przydatnym markerem agresywności gruczolaków przysadki. (Endokrynol Pol 2018; 69 (5): 530–535)
Słowa kluczowe: gruczolak przysadki, skala Knospa, topoizomeraza IIα, naciekanie zatok jamistych
Introduction
Pituitary adenomas
Pituitary adenomas are benign tumours that represent 
10–20% of all intracranial neoplasms treated surgically, 
and are the most common lesions found in the sellar 
area [1–3]. Microadenomas are tumours with diameter 
less than 1 cm. Larger tumours, referred to as ‘macroad-
enomas’, extend suprasellarly causing compression of 
the optic chiasm, may grow into the third ventricle, 
damage the hypothalamus, and extend laterally into 
the cavernous sinuses (CS) [4–7]. 
Borys M. Kwinta M.D., Ph.D., Department of Neurosurgery and Neurotraumatology, Jagiellonian University Medical College,  
Botaniczna 3, Kraków Poland, tel.: +48 12 424 8662; e-mail: bmkwinta@gmail.com
531
Endokrynologia Polska 2018; 69 (5)
PR
A
C
E 
O
RY
G
IN
A
LN
E
treatment by a multidisciplinary team consisting of 
neurosurgeons, radiologists, radiotherapists, endocri-
nologists, and ophthalmologists. 
The group consisted of 44 females (61.1%) and 28 
males (38.9%) aged 18 to 84 years (mean age 46.9 years; 
45.1 years for females and 49.9 years for males). Thir-
teen patients (18.1%) were diagnosed with acromegaly, 
seven (9.7%) with Cushing’s disease, one (1.4%) with 
secondary hyperthyroidism, and one (1.4%) with preco-
cious puberty. Twenty-four patients (33.3%) presented 
significant hyperprolactinaemia, and the remaining 
26 (36.1%) were harbouring clinically non-functioning 
pituitary adenomas. All patients were operated micro-
surgically via transsphenoidal approach. On immu-
nohistochemistry eight (11.1%) tumours were positive 
for prolactin only, seven (9.7%) for growth hormone, 
two (2.8%) for ACTH, one (1.4%) for LH, one (1.4%) for 
FSH, and three (4.1%) for a-subunit. Twenty-one (29.2%) 
adenomas were plurihormonal. 
This study was conducted in accordance to the De-
claration of Helsinki (1964), and its design was approved 
by the local University Ethical Committee (protocol 
number KBET/157/B/2012).
Methods
Tumour size, invasiveness, and extension evaluation 
To assess pituitary adenoma size and invasiveness 
computed tomography (CT) and magnetic resonance 
(MR) images of sellar regions were analysed. 
Tumour size was evaluated in three orthogonal 
planes. The longest dimension in every plane was se-
lected. Tumour volume was assessed using the Di Chiro 
and Nelson’s equation: V = (p/6) * (x * y * z) [31], for 
the volume of a spheroid, where ‘x, y, z’ are the longest 
sizes on three orthogonal axes. 
The assessment of tumour invasiveness was con-
ducted according to the Hardy scale as modified by 
Wilson [7] and the Knosp scale, both of which are 
based on CT and MRI coronal sections [8]. The side 
of the tumour with higher grading according to the 
Knosp grading scale was chosen for further analysis 
(Figure 1).
Morphometric analysis of topoisomerase IIα 
expression
The pituitary adenoma tissue samples obtained dur-
ing surgery were evaluated in the Neuropathology 
Department of the JUMC. Monoclonal immunoglobulin 
G‐class antibodies directed against C‐terminal domain 
of human topoisomerase (NCL-TOPOIIA, Novo‐castra, 
Novocastra Laboratories Ltd., New Castle upon Tyne, 
United Kingdom) was performed in 1:30 dilution (1:30). 
The antigen was retrieved at 95°C in citrate buffer (pH 
= 6.0). Overnight incubation with primary antiserum 
Approximately 6–10% of adenomas infiltrate CS 
[8–10]. CS invasion usually makes complete surgical 
removal of adenomas impossible, and in such cases 
alternative therapies, such as radiation, need to be ap-
plied. Tumour size itself is not an indicator of aggressive 
clinical behaviour [11]. Hence, evaluation of CS invasion 
is crucial for pituitary adenoma treatment planning and 
further prognosis [12].
Adenomas more prone to aggressive behaviour 
are: both growth hormone and prolactin secreting 
(acidophil stem cell adenomas), growth hormone secret-
ing (scant grainy type adenomas), silent corticotroph 
adenomas, and silent adenomas subtype III [13–15]. 
Pituitary cancers are extremely rare [16] and represent 
about 0.2% of all lesions in this location [17]. 
Markers of aggressiveness
Currently, reliable markers of aggressive adenoma 
behaviour are lacking [18]. Cytological markers of ag-
gressiveness, i.e. mitoses, polymorphism, or giant cells, 
are rarely found and are not linked to local invasiveness 
[2, 11]. The World Health Organisation pituitary ad-
enoma classification discriminates between typical and 
atypical adenomas based on the Ki-67 labelling index 
cut-off value of 3% [15, 19]; however, further research 
indicated low sensitivity of this test [20–22]. The work 
of Paek et al. did not confirm the relation between the 
Ki-67 labelling index and infiltration of the CS [18]. 
Little attention is paid to another potential marker 
— topoisomerase IIα. This is a nuclear enzyme main-
taining chromatin loop homeostasis during DNA 
replication [23]. It is widely used for the evaluation of 
the proliferation level of many neoplasms, for exam-
ple breast cancer, laryngeal cancer, and endometrial, 
haematopoietic, and central nervous system (CNS) 
neoplasms [24–28]. Topoisomerase IIα is also a target 
for oncological therapies [29, 30]. Patients with adeno-
mas with high expression of topoisomerase IIα might 
be more sensitive to drugs inhibiting this enzyme. It 
has been noted that the sensitivity of adenoma cells to 
topoisomerase IIα inhibitors depends on topoisomerase 
IIα expression in the tumour cells [30]. 
The presented study evaluates the relation between 
CS invasion and immunoexpression of topoisomerase 
IIα in pituitary adenomas — a potential marker of tu-
mour aggressiveness. 
Material and methods
Material
This retrospective study included 72 patients who 
underwent pituitary surgery in the Neurosurgery and 
Neurotraumatology Department of the JUMC between 
2007 and 2015. All patients were qualified for surgical 
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(NCL-TOPOIIA) at 2–8°C was followed by incubation 
with a secondary biotinylated antibody for 30 minutes. 
Avidin–biotin complex horseradish peroxidase (30 
minutes) with diaminobenzidine tetrahydrochloride 
was applied as chromogen. Slides were counterstained 
with haematoxylin.
After immunohistochemical staining, slides were 
analysed with an optical microscope, Nikon Optishot-2 
at 200x magnification. Nondiagnostic fragments (pres-
ence of normal pituitary tissue, fibrosis, haemorrhage, 
etc.) were excluded from further analyses. The mor-
phometric evaluation was performed only if at least 
one field of view at 200x magnification included ade-
noma material without thermal or mechanical damage 
and without massive necrotic or haemorrhagic lesions. 
If a sample was not suitable for assessment, staining 
was repeated after cutting another section from the 
specimen.
Topoisomerase IIα expression was assessed manu-
ally using an optical microscope with morphometric 
grid divided into 16 fields of equal area covering the 
entire field of view at 400x magnification. The number of 
stained cells and the total number of cells were counted 
for each field in five most suitable areas of the immu-
nostained slide. The topoisomerase IIα cell index was 
calculated as the percentage of cells exhibiting positive 
immunohistochemical reaction (Figure 2). 
Figure 1. Sellar MRI T1 C. As an example, the MRI plane shows 
sections through the CS and both intracavernous and intracranial 
carotid artery segments. Knosp grading: right side 3, left side 0
Rycina 1. Rezonans magnetyczny siodła tureckiego (T1). Na 
przykładzie uwidoczniono przekrój przez zatoki jamiste oraz 
śródjamisty i śródczaszkowy odcinek tętnic szyjnych wspólnych. 
Zaawansowanie wg skali Knospa: strona prawa — stopień 3, 
strona lewa — stopień 0
Figure 2. Immunostaining for topoisomerase IIα in pituitary 
adenoma (200x magnification)
Rycina 2. Barwienie w kierunku topoizomerazy IIα w gruczolaku 
przysadki (powiększenie 200x)
Statistical methods
Statistical analyses were performed using STATISTICA 
12. Because assumptions for a parametric test were 
not valid according to Shapiro-Wilk test of norma-
lity, all data were evaluated by non-parametric tests. 
Mann-Whitney U test and Kruskall-Wallis analysis of 
variance as a multiple-comparison method were used 
to compare the topoisomerase IIα expression between 
micro- and macroadenomas and between all of the 
Hardy scale grades. The Spearman test was used to 
assess the statistical significance of the correlation 
between the Knosp scale grading, as well as adenoma 
size and topoisomerase IIα expression. A p value < 0.05 
was considered statistically significant.
Results
The median tumour size was 2793 mm3 (IQR: 245–6703 
mm3). Macroadenomas (adenomas larger than 1 cm) 
were diagnosed in 51 cases (70.84%), while microade-
nomas were found in 21 cases (29.16%). 
The results of tumour invasiveness evaluation ac-
cording to the tumour Hardy-Wilson and Knosp scales 
are presented in Tables I and II, respectively.
Topoisomerase IIα expression was observed in 48 
out of 72 cases. No significant differences (p = 0.13) in 
the topoisomerase IIα expression cell index with respect 
to patient gender (female 0.31% vs. male 0.56%) were 
observed.
There was a significant correlation between the Knosp 
scale degree and topoisomerase IIα expression index 
(Spearman R = 0.3611, p = 0.0018. The Kruskal-Wallis H 
test (p = 0.0072) followed by Dunn’s test showed that only 
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grades 3 and 4, which correspond with the true invasion 
of the tumour into the CS, tended to correlate with an 
increased topoisomerase IIα expression indices (Figure 3).
The Kruskal-Wallis H test (p = 0.0034) followed by 
Dunn’s test showed that a significant increase in topoi-
somerase IIα expression was not observed in tumours 
classified as grade A, B, C, and D on the Hardy scale. 
However, there was a significant (p = 0.0143) expres-
sion increase in tumours classified as grade E (Figure 4).
The topoisomerase IIα expression correlated with 
tumour size (Spearman R = 0.4117, p < 0.001). Higher 
values of expression indices were observed in macroad-
enomas, as compared to microadenomas (p = 0.0003).
Table I. Pituitary adenoma invasiveness in the study group according to Hardy scale, as modified by Wilson [7]
Tabela I. Ocena wielkości gruczolaków przysadki w badanej grupie wg skali Hardy’ego (modyfikacja Wilsona) [7]
Invasion Extension Degree % of evaluated 
subjects
Floor of 
sella intact
I — I sella normal or focally expanded, 
tumour < 10 mm 
Suprasellar 0 — no I 0 29.17
II — sella enlarged, tumour ≥ 10 mm A — expansion into suprasellar cistern: tumour < 
10 mm above the sella, taking 25% of chiasmatic 
cistern 
II 0 8.33
II A 11.11
II B 6.94
II D 1.39
Sellar 
floor 
occupied
III — localised perforation of sellar floor B — anterior recesses of 3rd ventricle 
obliterated, tumour < 20 mm above the sella, 
taking 50–70% of chiasmatic cistern 
III A 5.56
III B 5.56
III C 5.56
III E 1.39
IV — diffuse destruction of sellar floor C — displacement of 3rd ventricle, tumour < 30 
mm above the sella, reaching foramina of Monro
IV B 4.17
IV C 5.56
IV D 8.33
IV E 6.94
V — spread via cerebrospinal fluid or 
blood-borne 
Parasellar D — intracranial, intradural, anterior, middle, or 
posterior fossa occupation
V 0
E — extradural, inside or beneath cavernous sinus 
Figure 3. Topoisomerase II-α expression in relation to the Knosp 
grading scale
Rycina 3. Ekspresja topoizomerazy IIα w zależności od 
zaawansowania według skali Knospa
Table II. Pituitary adenoma invasiveness according to Knosp 
scale [8]
Tabela II. Ocena inwazyjności gruczolaków przysadki według 
skali Knospa [8]
Degree MRI — coronal plane through the centre 
of sella turcica
No of 
patients (%)
0 No cavernous sinus involvement, tumour 
does not exceed line tangent to the medial 
outlines of intra- and supracavernous 
internal carotid artery (ICA)
40 (55.56)
1 Tumour does not exceed the line connecting 
centres of intra- and supracavernous ICA
6 (8.33)
2 Tumour does not exceed the line tangent 
to the lateral outlines of intra- and 
supracavernous ICA
11 (15.28)
3 Tumour crosses the line tangent to the 
lateral outlines of intra- and supracavernous 
ICA
12 (16.67)
4 Total encasement of the intracavernous ICA 3 (4.17)
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Discussion
The study correlates CS invasion by pituitary adenoma 
with topoisomerase IIα expression as a predictor of 
tumour aggressiveness. 
In many papers, different MRI criteria were used 
to assess CS invasion by pituitary adenomas [8, 9, 
12, 32]. In this study, we used the Hardy-Wilson 
classification and the Knosp scale. The radiological 
evaluation of pituitary adenoma growth allows the 
assessment of the possible radicality of tumour resec-
tion [33]. The Hardy scale indicates the degree of the 
sellar floor invasion. Wilson’s modification of this 
scale shows the advancement of suprasellar growth. 
The Knosp scale, on the other hand, specifies the 
extension of the tumour into the CS and the internal 
carotid arteries encasement, which directly affect the 
chances of complete resection. The reference point 
for the Knosp scale assessment is the coronal plane, 
which runs through the centre of the sella turcica [8]. 
Modern studies comparing MRI with intraoperative 
findings acknowledge the utility of the Knosp group’s 
findings concerning the lateral intercarotid line as 
a good marker of CS invasion [8, 12, 33]. In the study 
of Cottier et al., crossing the lateral intercarotid line by 
a tumour was an indicator of CS invasion (PPV 85%, 
NPV 95%) [33]. This is consistent with the presented 
results because it corresponds with degrees 3 and 4 
of the Knosp scale.
This study provides evidence that topoisomerase 
IIα expression was higher in tumours classified as 
grade 3 and grade 4 on the Knosp scale, which is 
concordant with CS occupation. A significant increase 
in topoisomerase IIα expression indices was not ob-
served in tumours classified as grade A, B, and C on 
the Hardy scale, i.e. in adenomas characterised by 
intra- and suprasellar growth. However, there was 
a significant topoisomerase IIα expression increase in 
tumours classified as grade E (occupying the CSI). It 
could be said that the topoisomerase IIα expression 
index is correlated more with invasiveness than with 
extensiveness).
To date, only a few studies have investigated 
topoisomerase IIα expression in pituitary adenomas. 
Sarkar et al. showed that MIB-1 proliferation index, 
p53 expression, and elevated mitotic index are factors 
correlated with parasellar invasion [34]. Intrasellar 
invasion in his study was not related to any immuno-
cytochemical marker [34]. In the studies of Landolt et 
al., Yilmaz et al., and Moldovan et al. a higher Ki-67 
labelling index in invasive pituitary adenomas was 
found [35–37]. In the study conducted by Wolfsberger 
et al., the MIB-1 proliferation index, unlike the topoi-
somerase IIα expression, was significantly higher in 
the group of invasive adenomas [38]. However, this 
group was characterised not only by intraoperative 
signs of CS invasion but also by intraoperative signs of 
dura and bone infiltration [38]. Simultaneously, in the 
same paper, a strong correlation between MIB-1 and 
topoisomerase IIα was reported [38]. Trofimiuk et al. 
presented a relationship between the topoisomerase 
IIα expression level and the tumour size and inva-
siveness [39]. In their study, prospective analysis was 
performed, and topoisomerase IIα index exceeding 
1% was assessed as a prognostic factor of pituitary 
adenoma recurrence [39]. In the study of Vidal et al., 
topoisomerase IIα expression was significantly higher 
in invasive tumours [30], which is also consistent with 
the results presented in our study.
Conclusions
From the clinical perspective, CS occupation is 
a very important factor that affects surgical procedure 
radicality and safety, and consequently the postopera-
tive course and prognosis. As can be concluded from 
the data obtained from our study, topoisomerase IIα 
expression correlates with CS invasion and might be 
a useful marker in the assessment of aggressive pitui-
tary adenoma. A further prospective study concerning 
topoisomerase IIα expression in recurrent tumours is 
needed.
Figure 4. Topoisomerase II-α expression in relation to the Hardy 
grading scale
Rycina 4. Ekspresja topoizomerazy IIα w zależności od 
zaawansowania według skali Hardy’ego
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